Gateway 2011: Grand River Aseptic Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Grand River Aseptic Manufacturing


  1. General Company Company Description:
  2. Grand River Aseptic Manufacturing is a parenteral contract manufacturer supporting new product development and small batch production. With a state‐of‐the‐art cleanroom and highly trained staff, Grand River Aseptic Manufacturing provides small scale clinical trial materials aseptically filled into vials and lyophilization for the pharmaceutical and biopharmaceutical markets.

    Grand River specializes in pre‐clinical, phase I through III clinical trials, and small scale commercial production quantities. We offer the following services for clinical, small scale, and commercial‐stage products: Sterile product development and manufacture, Lyophilization, Terminal sterilization and Analytical and microbiological services.



  1. Technical Services:

    • Sterile product development and manufacture
    • Lyophilization of vials 2 to 50 mL
    • Terminal sterilization
    • Analytical and microbiological services
    • Aseptic filling of vials 2 to 50 mL
    • Formulation development
    • Test method development and validation
    • Process development and validation
    • Controlled temperature storage
    • On-site warehouse and material storage
    • Regulatory support

  1. Facilities:
  2. Our Grand Rapids, Michigan facility includes:

    • 11,400-ft2 cGMP FDA registered facility
    • Class 100 aseptic filling suite
    • Class 10,000 processing area
    • Formulation Suite
    • Preparation Lab
    • Steam Sterilizer
    • USP Compliant WFI System
    • IMA Edwards Lyophilizer with CIP capabilities (31 ft2)
    • Capmatic Bambino Filler and Capper
    • PennTech - RW-500 Vial Washer
    • Lytzen Depyrogenation Oven

  1. Major Products/Services:
  2. Grand River specializes in pre‐clinical, phase I through III clinical trials, and small scale commercial production quantities. We offer the following services for clinical, small scale, and commercial‐stage products: Sterile product development and manufacture, Lyophilization, Terminal sterilization and Analytical and microbiological services.


  1. Markets Served:
  2. Grand River Aseptic Manufacturing serves the global pharmaceutical and biopharmaceutical industries.


PDF/Online Documents

Grand River Profile Sheet

Innovation Michigan Finalist: Grand River Aseptic Manufacturing

Grand River Aseptic Gains FDA Registration

Visit us at: Booth 1342
If you would like to schedule a personal meeting during the 2011 AAPS show please call or email: Greg Gonzales at (240) 344-9412 / ggonzales@grandriverasepticmfg.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search

Click here